Atossa Therapeutics logo
Atossa Therapeutics ATOS
$ 4.43 0.0%

Quarterly report 2025-Q3
added 11-12-2025

report update icon

Atossa Therapeutics Net Debt 2011-2026 | ATOS

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Atossa Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - -39.6 M -12.5 M -10.4 M -7.22 M -3.03 M -3.72 M -8.38 M -6.32 M -1.73 M -906 K

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-906 K -39.6 M -9.38 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
116 M $ 6.03 -1.55 % $ 885 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
11.9 M $ 19.2 -11.52 % $ 554 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
-26.7 M $ 10.89 -30.36 % $ 530 M niderlandNiderland
GT Biopharma GT Biopharma
GTBP
-5.5 M $ 0.47 -2.41 % $ 892 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.74 3.6 % $ 1.12 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
-60.8 M $ 3.36 0.86 % $ 1.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-48.9 M $ 29.16 -3.54 % $ 1.69 B usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
-48.6 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
612 M - - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Alector Alector
ALEC
-47.4 M $ 2.19 -9.77 % $ 226 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
-7.85 M $ 1.38 -0.72 % $ 63.3 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
-35.2 M $ 4.21 -2.32 % $ 299 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
131 M - -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-3.44 M $ 0.84 -4.24 % $ 27.9 M israelIsrael
Viela Bio, Inc. Viela Bio, Inc.
VIE
-130 M - - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-189 M $ 13.98 1.27 % $ 5.7 B irlandaIrlanda
AbbVie AbbVie
ABBV
59.5 B $ 233.57 0.64 % $ 413 B usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
-19.9 M - - $ 8.14 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
-26.2 M $ 0.8 -11.6 % $ 38.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.83 5.37 % $ 4.53 M chinaChina
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.67 -1.38 % $ 2.61 B usaUSA